drugset / Trial / NCT01784120
A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate efficacy and toxicity of doxorubicin/Genexol-PM in metastatic breast cancer 1. Primary Purpose: response rate 2. Secondary purpose: toxicity, progression-free survival, overall survival
Timeline
- Start
- 2011-01
- Primary completion
- 2018-01
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Paclitaxel | Small molecule | — | — |